Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fennec Banks On EMA’s Seldom-Used PUMA For Sodium Thiosulfate

Executive Summary

Fennec Pharmaceuticals says that its new formulation of sodium thiosulfate for preventing cisplatin-induced hearing loss in children targets a critical unmet medical need.

You may also be interested in...



Fennec Prepared For Market As Pedmark Finally Gets FDA Nod

After successive CRLs in 2020 and 2021, the drug gained a broad label for hearing loss in children treated with cisplatin for localized, non-metastatic solid tumors.

Novel Combined Contraceptive Estelle Among Nine New Filings At EMA

Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."

Novel Combined Contraceptive Estelle Among Nine New Filings At EMA

Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel